GlaxoSmithKline (GSK) Australia and Monash University have partnered to create an innovative production method for vaccines at GSK’s new pilot vaccine facility in Boronia.
The Boronia GSK team and Monash University joined with other worldwide vaccine experts based in Belgium. The new method involves blow-fill-seal to create the vaccine. With one process, the teams can use this technology to make the container, inject the sterile liquid, and cap the container to guarantee its sterility.
This technology is a much more cost-efficient approach to producing sterile, high-quality materials in large quantities. It also manages to produce the vaccines with a small production footprint. There will no longer need to be asceptic components available in a supply chain.
“It’s wonderful for Monash to be part of this innovation,” Associated Professor David Morton said. “Thanks to the GSK team, our students and staff have had unique exposure to real-world challenges in advanced manufacturing and product development. This industrial environment is where such true high-impact Australian innovation thrives, and our future talent is created.”
If the new method is successful, it may decrease vaccine costs. This would enable children who live in developing countries around the world to have better accessibility to vaccines.
